Advertisement

Solange Peters, MD, PhD

Articles

The Exciting Future of NSCLC Treatment

November 23rd 2022

Closing their discussion, the panel shares where they think the NSCLC treatment landscape will be in the future, and what to look forward to.

A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations

November 16th 2022

The panel explains their approaches to treating patients with mutated NSCLC with immunotherapy.

The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC

November 16th 2022

Dr Johnson reviews data from the ARC-7 trial investigating an anti-PD-L1 plus anti-TGIT combination treatment for advanced NSCLC.

The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC

November 9th 2022

Drs Peters and Velcheti provide an overview of the role of anti-TGIT immunotherapies in NSCLC treatment.

Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy

November 9th 2022

Solange Peters, MD, explains the currently available treatment options for patients with advanced NSCLC after progression on immunotherapy.

POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC

November 2nd 2022

Melissa Johnson, MD, explains the design and outcomes of the multi-arm POSEIDON study, which featured a combination of 4 agents for the treatment of advanced NSCLC.

EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC

November 2nd 2022

Key opinion leaders discuss data from the EMPOWER-Lung-3 study investigating the use of cemiplimab plus chemotherapy in both squamous and non-squamous NSCLC.

KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC

October 26th 2022

Dr Velcheti reviews data on the chemoimmunotherapy treatment of squamous NSCLC from the KEYNOTE-407 study.

CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC

October 26th 2022

Dr Vamsidhar Velcheti explains the 4-year data updates to the CheckMate 227 trial, which investigated PD-L1 monotherapy plus chemotherapy for advanced NSCLC.

Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors

October 19th 2022

Drs Peters and Johnson discuss recent updates in the treatment of advanced NSCLC with single- and dual-agent immunotherapy regimens.

Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC

October 19th 2022

Dr Melissa Johnson and Dr Myung-Ju Ahn emphasize the importance of a multidisciplinary approach to treatment and biomarker testing for patients with early-stage NSCLC.

Novel HER2-Targeted Therapies for NSCLC

October 17th 2022

Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.

Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC

October 17th 2022

The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.

Unmet Needs in NSCLC Therapy

October 17th 2022

Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.

The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC

October 17th 2022

Vamsidhar Velcheti, MD, summarizes recent data on adjuvant immunotherapy treatment in resectable NSCLC.

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial

October 17th 2022

Dr Myung-Ju Ahn describes the unique design and outcomes of the NEOCoast study that is evaluating immunotherapy regimens in the neoadjuvant and adjuvant settings.

Major Adverse Events of Anti-HER2 Therapies

October 10th 2022

Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.

HER2-Targeted Therapies in NSCLC

October 10th 2022

Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.

Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC

October 7th 2022

Drs Vamsidhar Velcheti and Solange Peters discuss the optimum length for immunotherapy treatment in resectable NSCLC, highlighting the issue of payer authorizations.

Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

October 7th 2022

Oncologists explain data from the NADIM II and AEGAN clinical trials investigating treatments for neoadjuvant immunotherapy in resectable NSCLC.

Advertisement
Advertisement